These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 26894045)
1. The infantile-onset form of Pompe disease: an autopsy diagnosis. Dos Santos OC; Schultz R Autops Case Rep; 2015; 5(4):45-51. PubMed ID: 26894045 [TBL] [Abstract][Full Text] [Related]
2. [Variability in the clinical presentation of Pompe disease in infancy: two case reports and response to treatment with human recombinant enzyme]. Moreno-Medinilla E; Berzosa-López R; Mora-Ramírez MD; Blasco-Alonso J; Martínez-Antón J Rev Neurol; 2014 Dec; 59(11):503-7. PubMed ID: 25418145 [TBL] [Abstract][Full Text] [Related]
3. A New Mutation Causing Severe Infantile-Onset Pompe Disease Responsive to Enzyme Replacement Therapy. Moravej H; Amirhakimi A; Showraki A; Amoozgar H; Hadipour Z; Nikfar G Iran J Med Sci; 2018 Mar; 43(2):218-222. PubMed ID: 29749992 [TBL] [Abstract][Full Text] [Related]
5. Novel Mutation in the Feline Rakib TM; Islam MS; Tanaka S; Yabuki A; Pervin S; Maki S; Faruq AA; Tacharina MR; Yamato O Animals (Basel); 2023 Apr; 13(8):. PubMed ID: 37106898 [TBL] [Abstract][Full Text] [Related]
6. [Clinical and molecular genetic study on two patients of the juvenile form of Pompe disease in China]. Qiu JJ; Wei M; Zhang WM; Shi HP Zhonghua Er Ke Za Zhi; 2007 Oct; 45(10):760-4. PubMed ID: 18211760 [TBL] [Abstract][Full Text] [Related]
8. [A retrospective study of six patients with late-onset Pompe disease]. Saux A; Laforet P; Pagès AM; Figarella-Branger D; Pellissier JF; Pagès M; Labauge P Rev Neurol (Paris); 2008 Apr; 164(4):336-42. PubMed ID: 18439925 [TBL] [Abstract][Full Text] [Related]
9. New insights into therapeutic options for Pompe disease. Richard E; Douillard-Guilloux G; Caillaud C IUBMB Life; 2011 Nov; 63(11):979-86. PubMed ID: 22002928 [TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation. But WM; Lee SH; Chan AO; Lau GT Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354 [TBL] [Abstract][Full Text] [Related]
11. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease. Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324 [TBL] [Abstract][Full Text] [Related]
12. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease]. Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935 [TBL] [Abstract][Full Text] [Related]
13. Case Report: Identification of Compound Heterozygous Mutations in a Patient With Late-Onset Glycogen Storage Disease Type II (Pompe Disease). Zhang H; Chen J; Zhu Y; Ma X; Zhong W Front Neurol; 2022; 13():839263. PubMed ID: 35386406 [TBL] [Abstract][Full Text] [Related]
14. Post-mortem diagnosis of Pompe disease by exome sequencing in a Moroccan family: a case report. Adadi N; Sahli M; Egéa G; Ratbi I; Taoudi M; Zniber L; Jdioui W; El Mouatassim S; Sefiani A J Med Case Rep; 2018 Oct; 12(1):322. PubMed ID: 30371346 [TBL] [Abstract][Full Text] [Related]
15. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988 [TBL] [Abstract][Full Text] [Related]
16. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Kishnani PS; Corzo D; Nicolino M; Byrne B; Mandel H; Hwu WL; Leslie N; Levine J; Spencer C; McDonald M; Li J; Dumontier J; Halberthal M; Chien YH; Hopkin R; Vijayaraghavan S; Gruskin D; Bartholomew D; van der Ploeg A; Clancy JP; Parini R; Morin G; Beck M; De la Gastine GS; Jokic M; Thurberg B; Richards S; Bali D; Davison M; Worden MA; Chen YT; Wraith JE Neurology; 2007 Jan; 68(2):99-109. PubMed ID: 17151339 [TBL] [Abstract][Full Text] [Related]
17. Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings. Teng YT; Su WJ; Hou JW; Huang SF Chang Gung Med J; 2004 May; 27(5):379-84. PubMed ID: 15366815 [TBL] [Abstract][Full Text] [Related]
18. Enzyme Replacement Therapy (ERT) on Heart Function Changes the Outcome in Patients with Infantile-Onset Pompe Disease: A Familial History. Lecis M; Rossi K; Guerzoni ME; Mariotti I; Iughetti L Case Rep Pediatr; 2023; 2023():8470341. PubMed ID: 36845322 [TBL] [Abstract][Full Text] [Related]
19. Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form. Verloes A; Massin M; Lombet J; Grattagliano B; Soyeur D; Rigo J; Koulischer L; Van Hoof F Am J Med Genet; 1997 Oct; 72(2):135-42. PubMed ID: 9382133 [TBL] [Abstract][Full Text] [Related]
20. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]